RxDoctor Payments Data

Sai Chundu, MD

Psychiatry · Corona, CANPI 1609968460

Payments from drug & device makers

$5,365in general payments, 2019–2025

Across 353 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$681
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$501
  • Teva Pharmaceuticals USA, Inc.$496
  • Neurocrine Biosciences, Inc.$435
  • AbbVie$417
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$5,24898%
  • Education$1172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,365 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$49,259
Medicare patients
160
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate76$241,736
IngrezzaValbenazine Tosylate27$221,849
AustedoDeutetrabenazine11$77,024
Abilify MaintenaAripiprazole20$60,461
Aripiprazole461$28,871
RexultiBrexpiprazole11$16,620
Quetiapine Fumarate522$14,198
VyvanseLisdexamfetamine Dimesylate19$8,352
Bupropion XlBupropion Hcl372$7,969
Duloxetine Hcl303$6,288
Oxcarbazepine115$5,694
Clomipramine Hcl11$5,585
Trazodone Hcl383$5,294
Hydroxyzine Hcl229$4,906
Divalproex Sodium ErDivalproex Sodium72$4,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$221$241,73676 claims
Neurocrine Biosciences, Inc.Ingrezza$435$221,84927 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$681$77,08131 claims
Teva Pharmaceuticals USA, Inc.Austedo$496$77,02411 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$272$8,35219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →